tbuckley/cabot-search huggingface dataset:
School District Crisis Preparedness, Response, and Recovery Plans — United States, 2012
Authors: Brenda Silverman, Brenda Chen, Nancy Brener, Judy Kruger, Nevin Krishna, Paul Renard, Sandra Romero-Steiner, Rachel Nonkin Avchen
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

The unique characteristics of children dictate the need for school-based all-hazards response plans during natural disasters, emerging infectious diseases, and terrorism (1-3). Schools are a critical community institution serving a vulnerable population that must be accounted for in public health preparedness plans; prepared schools are adopting policies and plans for crisis preparedness, response, and recovery (2-4). The importance of having such plans in place is underscored by the development of a new Healthy People 2020 objective (PREP-5) to "increase the percentage of school districts that require schools to include specific topics in their crisis preparedness, response, and recovery plans" (5). Because decisions about such plans are usually made at the school district level, it is important to examine district-level policies and practices. Although previous reports have provided national estimates of the percentage of districts with policies and practices in place (6), these estimates have not been analyzed by U.S. Census region* and urbanicity.(†) Using data from the 2012 School Health Policies and Practices Study (SHPPS), this report examines policies and practices related to school district preparedness, response, and recovery. In general, districts in the Midwest were less likely to require schools to include specific topics in their crisis preparedness plans than districts in the Northeast and South. Urban districts tended to be more likely than nonurban districts to require specific topics in school preparedness plans. Southern districts tended to be more likely than districts in other regions to engage with partners when developing plans. No differences in district collaboration (with the exception of local fire department engagement) were observed by level of urbanicity. School-based preparedness planning needs to be coordinated with interdisciplinary community partners to achieve Healthy People 2020 PREP-5 objectives for this vulnerable population.
Allergy testing in children with persistent asthma: comparison of four diagnostic methods
Authors: A. Önell, A. Whiteman, B. Nordlund, F. Baldracchini, G. Mazzoleni, G. Hedlin, H. Grönlund, J. R. Konradsen
Journal: Allergy (2016)

Multiple allergic sensitizations are common in persistent childhood asthma, and thorough assessment of allergy is crucial for optimal care of these children. Microarray testing offers opportunities for improved sIgE characterization, which has been projected to be useful in the management of multisensitized patients.The aim of this study was to investigate the accuracy and information obtained by two microarray platforms applied on a well-characterized pediatric asthma cohort.Seventy-one children were recruited from a nationwide Swedish study on severe childhood asthma. Severe (n = 40) and controlled (n = 31) asthmatics were assessed for allergic sensitization by two microarray systems (Microtest and ISAC) and by two standard diagnostic methods (ImmunoCAP and skin prick test). Data on clinical history, physical examination, spirometry, asthma control test, and doctor's diagnosis were collected. Results from the four diagnostic methods were analyzed and compared.A high prevalence of allergic sensitization was observed in this cohort. The pairwise concordance between two methods was 90-92% independently of methods compared. The sensitivity of the four methods against doctor's diagnosis was 0.77-0.88, and the specificity was 0.97-0.99. Microarray methods provided new information in 47% of the sensitized children in comparison with results obtained by standard diagnostic methods.The high prevalence of food and respiratory sensitization supports the clinical guideline recommendation that allergies should be evaluated in all children with suspected asthma. The microarray platforms studied here demonstrated acceptable accuracy and provided refined IgE characterization in 47% of the patients compared to standard extract-based methods.
Expression of glutamine synthetase in hepatocyte progenitor cells derived from canal of Hering
Authors: Cheng‐Maw Ho, Hui‐Ling Chen
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. To the Editor: We rejoiced in reading the Liver Capsule by Alvaro et al.1 published in hepatology. Glutamine synthetase (GS) is expressed in a rim of hepatocytes surrounding hepatic veins in normal human liver.1 However, GS does express in activated hepatic progenitor cells from the canal of Hering in human cirrhosis.3 These progenitor cells express epithelial cell adhesion molecule and GS away from the hepatic vein, of which the endothelium is cluster of differentiation 34‐negative.3 Hybrid hepatocytes (SOX9low) of periportal normal liver are found to express GS.4 We are interested in whether the hybrid hepatocytes or hepatoblasts which express epithelial cell adhesion molecule would also express GS as they differentiate toward mature hepatocytes.
Phase II trial evaluating gemcitabine-ifosfamide-cisplatin as induction treatment for mediastinoscopy proven stage IIIa-N2 non-small cell lung cancer
Authors: Sofie Derijcke, Johan Vansteenkiste, Paul De Leyn, Yolande Lievens, Kristiaan Nackaerts, Christophe Dooms
Journal: Journal of Thoracic Oncology (2011)
Activation of GLP-1 Receptor Enhances Neuronal Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1
Authors: Jenq-Lin Yang, Wei-Yu Chen, Yin-Ping Chen, Chao-Ying Kuo, Shang-Der Chen
Journal: Theranostics (2016)

Glucagon-like peptide-1 (GLP-1) is an intestinal-secreted incretin that increases cellular glucose up-take to decrease blood sugar.Recent studies, however, suggest that the function of GLP-1 is not only to decrease blood sugar, but also acts as a neurotrophic factor that plays a role in neuronal survival, neurite outgrowth, and protects synaptic plasticity and memory formation from effects of β-amyloid.Oxidative DNA damage occurs during normal neuron-activity and in many neurological diseases.Our study describes how GLP-1 affected the ability of neurons to ameliorate oxidative DNA damage.We show that activation of GLP-1 receptor (GLP-1R) protect cortical neurons from menadione induced oxidative DNA damage via a signaling pathway involving enhanced DNA repair.GLP-1 stimulates DNA repair by activating the cyclic AMP response element binding protein (CREB) which, consequently, induces the expression of apurinic/apyrimidinic endonuclease 1 (APE1), a key enzyme in the base excision DNA repair (BER) pathway.In this study, APE1 expression was down-regulated as a consequence phosphatidylinositol-3 kinase (PI3K) suppression by the inhibitor LY294002, but not by the suppression of MEK activity.Ischemic stroke is typically caused by overwhelming oxidative-stress in brain cells.Administration of exentin-4, an analogue of GLP-1, efficiently enhanced DNA repair in brain cells of ischemic stroke rats.Our study suggests that a new function of GLP-1 is to elevate DNA repair by inducing the expression of the DNA repair protein APE1.
Leonard Robert Payne
Authors: Alison Payne
Journal: BMJ (2016)

Leonard Robert Payne (“Bob”) worked at Fort Dunlop as a scientist during the war and moved to Dunlop Rubber’s office in Lima for several years after the war ended. He told great tales about his Latin American adventures, and after his death I found some remarkable photos of him at a deserted Machu Picchu with his expat friends.

A devout Christian, he considered a religious life but then opted for his lifelong ambition of medicine and studied at St Andrews. While working at Arbroath Infirmary, he met a young nurse from Aberdeen, who went against …
Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies
Authors: Partow Kebriaei, Stefan O. Ciurea, Mary Helen Huls, Harjeet Singh, Simon Olivares, Shihuang Su, Matthew J. Figliola, Pappanaicken Kumar, Bipulendu Jena, Marie-Andree Forget, Sonny Ang, Rineka Jackson, Tingting Liu, Ian K. McNiece, Gabriela Rondon, Perry Hackett, Hagop M. Kantarjian, Dean A. Lee, Uday R. Popat, Amin Alousi, Betul Oran, Nina Shah, Chitra M. Hosing, David Marin, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin
Journal: Blood (2015)
VAMP2 is implicated in the secretion of antibodies by human plasma cells and can be replaced by other synaptobrevins
Authors: Laura Gómez-Jaramillo, Raquel Romero-García, Gema Jiménez-Gómez, Lisa Riegle, Ana Belén Ramos-Amaya, José Antonio Brieva, Marie Kelly-Worden, Antonio Campos-Caro
Journal: Cellular and Molecular Immunology (2016)
D1-05: Irinotecan, carboplatin, and bevacizumab in untreated extensive-stage small-cell lung cancer
Authors: David R. Spigel, John D. Hainsworth, Howard A. Burris, Denise A. Yardley, Cindy Farley, Christina Meng, F Anthony Greco
Journal: Journal of Thoracic Oncology (2007)
Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR
Authors: J Tabernero, P Schoffski, F Rojo, Ernst de Bruijn, FJ Ramos, Herlinde Dumez, T Macarulla, Hans Prenen, E Casado, Gunther Guetens, Peralta, J Jimenez, JM del Campo, N Gascon, R Cajal, E Martinelli, E Jimenez, AT Van Oosterom, J Baselga
Journal: Clinical Cancer Research (2005)
P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis
Authors: A.C. Cheung, W.J. Lammers, G.M. Hirschfield, P. Invernizzi, A.L. Mason, C.Y. Ponsioen, A. Floreani, C. Corpechot, M.J. Mayo, A. Pares, P.M. Battezzati, F. Nevens, D. Thorburn, K.V. Kowdley, P.J. Trivedi, T. Kumagi, A. Lleo, N. LaRusso, K. Boonstra, N. Cazzagon, I. Franceschet, R. Poupon, L. Caballeria, K.D. Lindor, B.E. Hansen, H.L. Janssen, H. Van Buuren
Journal: Journal of Hepatology (2015)
P1-256: The prevalence and risk factors of pneumonia after cytotoxic chemotherapy in advanced lung cancer patients
Authors: Jeong-Ok Lee, Dae-Young Kim, Myung Seo, Hyeon Deok Yi, Joo Gyu Lim, Yu-Jung Han Kim, Se-Hoon Lee, Dong-Wan Kim, Young Kim, Dae Seog Whan Heo
Journal: Journal of Thoracic Oncology (2007)
Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma
Authors: Madlen Jentzsch, Elena Ruschpler, Sabine Leiblein, Yvonne Remane, Jan-Phillip Stümpel, Georg-Nikolaus Franke, Simone Heyn, Nadja Jaekel, Susann Schulze, Song-Yau Wang, Wolfram Poenisch, Claudia Nehring, Sebastian Schwind, Dietger Niederwieser, Vladan Vucinic
Journal: Blood (2015)
Risk of dying from early prostate cancer is low regardless of treatment, study finds
Authors: Caroline White
Journal: BMJ (2016)

The risk of dying from early stage prostate cancer, detected by a prostate specific antigen (PSA) test, is very low—no more than 1% over 10 years—irrespective of whether the tumour is treated with surgery, radiotherapy, or active monitoring, concludes a study published in the New England Journal of Medicine .1

The results of the Prostate Testing for Cancer and Treatment (ProtecT) study show that National Institute for Health and Care Excellence (NICE) guidance on risk stratification for treatment may need to be revised, said the investigators.

The study involved 82 429 symptomless men aged 50 to 69, drawn from UK general practice lists and given a PSA test from 1999 to 2009. Localised prostate cancer was diagnosed in 2664 …
Cardiomyocyte-specific NOS3 Overexpression Protects Against Chronic Pressure Overload-induced LV Hypertrophy and Dysfunction
Authors: Stefan Janssens, Peter Pokreisz, Marijke Pellens, Pieter Vermeersch, P Jans, Hilde Gillijns, Luc Schoonjans, Frans Van de Werf, Desire Collen, KD Bloch
Journal: Circulation (2004)
Occult hepatitis B virus infection in patients with chronic liver disease.
Authors: Paulo Henrique Costa Diniz, Luciana Costa Faria, Paula Vieira Teixeira Vidigal, Marcelo Antonio Pascoal Xavier, Nayra Soares do Amaral, Alexandre Prado Resende, Agnaldo Soares Lima, Debora Marques Miranda, Teresa Cristina de Abreu Ferrari
Journal: Journal of Clinical Oncology (2013)

e15199 Background: Occult hepatitis B virus (HBV) infection is characterized by persistence of HBV DNA into the tissue of hepatitis B surface antigen-negative individuals. The clinical relevance of this infection is still under debate. In particular, the impact of occult HBV infection in cases of hepatocellular carcinoma (HCC) is uncertain. Methods: We investigated the prevalence of occult HBV in patients with chronic liver disease, with or without HCC, that were submitted to liver transplantation or partial hepatectomy in Alfa Institute of Gastroenterology from Clinical Hospital - UFMG - Brazil. We tested the presence of VHB DNA in liver sample using nested PCR in four different regions of viral genome (pre-S/S, pre –core/core, polymerase and X). We also tested these patients’serum for HVB antigens (HBsAg and HBeAg)and antibodies (anti-HBs, anti-HBe and anti-HBC). Results: Our studied population included 71 patients, 50 (70.4%) were male and had median age of 51±12.5 years. Cirrhosis etiology was alcoholic (22 cases, 32.4%), viral hepatitis (17 cases, 25%), cryptogenic (16 cases, 23.5%), autoimmune (10 cases, 14.7%) and 3 cases of other etiologies. HCC was found in 22 patients (31.4%). Viral DNA was detected in 4 cases (5.6%), three of them with HCC. Among these three cases viral DNA was found in non-tumoral area in two of them and in HCC sample in the other one. Conclusions: The prevalence of occult hepatitis B infection was high in our population of cirrhotic patients submitted to liver transplant, especially with associated HCC.
Connexin 43 Mediates White Adipose Tissue Beiging by Facilitating the Propagation of Sympathetic Neuronal Signals
Authors: Yi Zhu, Yong Gao, Caroline Tao, Mengle Shao, Shangang Zhao, Wei Huang, Ting Yao, Joshua A. Johnson, Tiemin Liu, Aaron M. Cypess, Olga Gupta, William L. Holland, Rana K. Gupta, David C. Spray, Herbert B. Tanowitz, Lei Cao, Matthew D. Lynes, Yu-Hua Tseng, Joel K. Elmquist, Kevin W. Williams, Hua V. Lin, Philipp E. Scherer
Journal: Cell Metabolism (2016)
P1-208: Sequential or concomitant chemo- and 3D conformal radiotherapy in limited stage small cell lung cancer
Authors: Mahmut Ozsahin, Mohamed Elhfid, Kaouthar Khanfir, Oscar Matzinger, Roger Stupp, Huu-Phuoc Do, Sabine Bieri, Rene O. Mirimanoff, Abderrahim Zouhair
Journal: Journal of Thoracic Oncology (2007)
Rhabdomyosarcoma of the Paratesticular Tissues
Authors: E. W. Irvine, Owen C. Berg, Richard Nelson
Journal: New England Journal of Medicine (1962)

RHABDOMYOSARCOMAS are generally classified as rare and fatal tumors. Horn and Enterline1 suggest that the infrequent incidence of this cancer could be attributed to failure in pathological diagnosis, since perseverance is often necessary for demonstration of cross-striations within the tumor cells.Most of these tumors arise in the head, neck and extremities. Only 4 have been reported in which the primary site was the scrotum or associated structures.1 2 3 Case ReportA 3 1/2-year-old boy was first seen in August, 1956, with a mass in the left scrotum of 1 month's duration. The impression was hydrocele on initial examination. The parents . . .
Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC).
Authors: Harry Raftopoulos, Joseph Aisner, Kirushna Kumar, Sanjay Goel, Christian Dittrich, Minish Jain, Prashanth Gopalakrishna, Paloma Salazar, Beverley Jones, Daniel Peter Petrylak
Journal: Journal of Clinical Oncology (2013)

e19145 Background: Eribulin mesylate as monotherapy has shown antitumor activity in patients with advanced NSCLC that progressed during or after platinum-based doublet chemotherapy (Spira AI et al. Clin Lung Cancer 2012; 13:31-38.). Following evidence of additive activity with eribulin and carboplatin in lung cancer cell lines, a phase Ib, dose-escalation study determined the maximum tolerated dose and optimum administration sequence of the combination as eribulin mesylate 1.1 mg/m 2 (0.97 mg/m 2 eribulin as free base) followed by carboplatin AUC 6. We report results from an extension arm that investigated the efficacy and safety of this combination in chemo-naïve patients with advanced NSCLC. Methods: Chemo-naïve patients with histologically or cytologically confirmed advanced NSCLC (stage IIIB or IV) with measurable disease were enrolled. Eribulin mesylate was administered intravenously (i.v.) on days 1 and 8 every 21 days, along with carboplatin i.v. on day 1. Efficacy assessments included best overall objective response rate (ORR; RECIST), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and duration of response (DOR). Adverse events (AEs) were also recorded. Results: 12 patients were accrued (11 male, 1 female) with a median age of 66.5 (range 42-74) years. For the 11 patients evaluable for efficacy, overall ORR was 27.3% (all partial responses) and DCR was 63.6%. Median (range) OS was 12.1 (1.6-12.1) months (5 patients still alive); PFS was 4.2 (0.03 + -5.8 + ) months (upper value censored as 1 patient still responding at final visit); and DOR was 2.9 (2.8-3.1 + ) months. The most common AEs ≥grade 3 were thrombocytopenia (n=6), neutropenia (n=5), febrile neutropenia (n=4), anemia (n=3), and dyspnea, hypokalemia, leukopenia, and pneumonia (n=2 each). Conclusions: The combination of eribulin and carboplatin yielded no unexpected safety findings. Given the evolving treatment practices for NSCLC, further studies involving larger numbers of patients are warranted, with consideration given to specific histologic subgroups. Clinical trial information: NCT00268905.
Zika Virus Is More Like Rubella Than Human Immunodeficiency Virus
Authors: Ben Z. Katz
Journal: JAMA Pediatrics (2016)

To the Editor I hate to disagree with my learned colleague Dr Peter Hotez,1 but I believe some of the analogies he presents in his JAMA Pediatrics article “What Does Zika Virus Mean for the Children of the Americas?” are exaggerated and misleading.1
Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).
Authors: Matt D. Galsky, Beth A. Hellerstedt, Mark Allen O'Rourke, Nicholas J. Vogelzang, Darren M. Kocs, Scott A. McKenney, Anton M. Melnyk, Thomas E. Hutson, Mary Ann Rauch, Yunfei Wang, Lina Asmar, Guru Sonpavde
Journal: Journal of Clinical Oncology (2012)

282 Background: Sunitinib (S) has single-agent activity in patients with advanced urothelial carcinoma (UC). Preclinical studies in UC demonstrate at least additive antitumor activity combining S with gemcitabine (G) or cisplatin (C). Methods: Patients with chemonaïve metastatic UC were enrolled in a multicenter phase II trial with overall response rate (ORR) as the primary endpoint. The initial dosing regimen, based on a phase I trial (Reck, 2010), was G 1000 mg/m 2 IV (Days 1 &amp; 8), C 70 mg/m 2 IV (Day 1), and S 37.5 mg PO daily (Days 1-14)/each 21-day cycle (up to 6 cycles), followed by S 37.5 mg daily until progression. Results: From December 2008 to August 2009, 15 eligible patients enrolled. Seven of 15 patients discontinued treatment early (median: 3 cycles) due to toxicity, most often due to recurrent neutropenia and thrombocytopenia. Intrapatient dose reductions were required for G (12/15), C (8/15), and S (10/15). Eight of 15 patients experienced serious adverse events. Based on the toxicity profile, enrollment was held and the dosing regimen was revised to G 800 mg/m 2 IV (Days 1 and 8), C 60 mg/m 2 IV (Day 1), S 37.5 mg PO daily (Days 1-14). From December 2009 to April 2011, 18 additional patients were enrolled. Despite the reduced starting doses, intrapatient dose reductions were required for G (13/18), C (9/18), and S (15/18). The most frequent Grade 3-4 toxicities for both groups were neutropenia (70%), thrombocytopenia (58%), and anemia (30%). Antitumor activity is shown in the Table. Median PFS was 7.9 and median OS was 13.8 months. Conclusions: Combination G+C+S is poorly tolerated and results in activity comparable to historical results with G+C alone. Supported in part by a grant from Pfizer Inc. [Table: see text]
Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.
Authors: R. R. Furman, J. C. Byrd, I. W. Flinn, S. E. Coutre, D. M. Benson, J. R. Brown, B. S. Kahl, N. D. Wagner-Johnston, N. A. Giese, A. S. Yu
Journal: Journal of Clinical Oncology (2010)

3032 Background: The class I phosphatidylinositol 3-kinase (PI3K) p110δ isoform is primarily expressed in cells of hematopoietic origin and has a key role in B cell maturation and function. CAL-101 is a potent and selective inhibitor of p110δ that inhibits PI3K signaling and induces apoptosis of primary CLL and AML cells and a range of leukemia and lymphoma cell lines. Methods: An ongoing phase 1 study enrolled previously treated patients with select hematologic malignancies in a standard sequential dose escalation/cohort expansion design. CAL-101 was administered orally twice-a-day continuously for 28 days per cycle. Results: At data cutoff, 57 patients were enrolled (NHL n=29, CLL n=18, AML n=10), 49% had refractory disease, median number of prior regimens= 4.5. Dose levels were 50 mg (n=3), 100 mg (n=3), 200 mg (n=34) and 350 mg (n=17). Clinical responses were seen at all dose levels. The objective response rate was 9/15 in indolent NHL, 6/7 in mantle cell lymphoma, and 4/17 in CLL, with 14/16 evaluable CLL patients having >50% reduction in lymphadenopathy (mean decrease=75%). Durable responses of >6 months have been reached in 5 patients, with 9/19 responders still on therapy. The dose limiting toxicity was reversible increases in serum transaminases in 21% of patients dosed at 200 mg and 350 mg; 6/8 patients resumed at a lower dose without recurrence of the transaminitis. Hematological toxicity was infrequent. Plasma exposure increased with dose. Phospho-AKT (T308) as a marker of PI3K activation was measured in cells from a subset of CLL patients with circulating lymphocytes and was reduced by >90% following dosing. Accrual is continuing and updated data will be presented. Conclusions: CAL-101, an oral selective PI3K p110δ inhibitor, shows promising activity with acceptable toxicity in patients with relapsed or refractory B-cell malignancies. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Calistoga Pharmaceuticals Calistoga Pharmaceuticals Calistoga Pharmaceuticals Calistoga Pharmaceuticals Calistoga Pharmaceuticals
The Effect of Temporary Elevated 17 B Estradiol (E2) Levels On the Coagulation System as Measured by D-Dimer in Women Undergoing in Vitro Fertilization.
Authors: Tamar Sokal-Arnon, Aliza Cassel, Evelyne Shabad, Zofnat Wiener-Megnazi, Ron Auslender, Martha Dirnfeld, Miriam Quitt
Journal: Blood (2009)
Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus
Authors: Ming-Ming Hu, Qing Yang, Xue-Qin Xie, Chen-Yang Liao, Heng Lin, Tian-Tian Liu, Lei Yin, Hong-Bing Shu
Journal: Immunity (2016)